Hva Skjer’a ?

Denne tråden er stengt for nye innlegg.
01.10.2021 kl 16:07
BioBull
BGBIO 26.10.2020 kl 09:14 1676387

225000 aksjer omsatt før 09:10 på stigende priser på en «negativ børsdag»....
Her er det definitivt noe som skjer - stay tuned...
Redigert 15.09.2021 kl 17:36 Du må logge inn for å svare
Rule
25.04.2021 kl 21:01 8001

vi ligger langt under de kursmål der udstikkes også selvom covid delen trækkes fra, så det er et hult kor.
Hayen
25.04.2021 kl 21:10 8038

"Efforts got off to a slow start, but interest grows with demand for a COVID pill"

https://www.medpagetoday.com/special-reports/exclusives/92224
BioBull
26.04.2021 kl 08:51 7104

Mens vi venter på Bemcentinib ...

bruk IVERMECTIN
“I also have my Ivermectine box ready at home ! To be combined with a microlide antibiotic ! Like azyrhromycine for instance”...

Over 4 Mrd doser uten bivirkninger.


Virker profylaktisk ( forebyggende ) og reduserer symptomer på COVID-19.
Blir noen i familien smittet bør alle andre ta IVERMECTIN
Ingen fare for overdoser, men kan virkning kan påvirkes av andre medisiner. (Sjekk på https://www.drugs.com/ )

https://www.tv2.no/a/11975167/

Dr Pierre Kory, Part 1, Steroids and anticoagulants
https://youtu.be/JMeP66gdc4o

Dr Pierre Kory, Part 2, Ivermectin
https://youtu.be/19DPijOoVKE
Redigert 28.04.2021 kl 15:21 Du må logge inn for å svare
mimer
26.04.2021 kl 08:58 7256

Ebastin & Ciclosporin: Mögliche Covid-Therapien ermittelt
Cynthia Möthrath, 20.04.2021 08:58 Uhr

Auch der Kinase-Inhibitor Dacomitinib, welcher gegen Lungenkrebs eingesetzt wird konnte positive Wirkungen zeigen, ebenso wie Bemcentinib, ein weiterer Kinase-Inhibitor.

https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/ebastin-ciclosporin-moegliche-covid-therapien-ermittelt-wirkstoff-screening/

klaesp
26.04.2021 kl 09:32 7130

long41 skrev Innlegget er slettet
Snart bare BEM igjen. Flott med litt oppgang, dog lav omsettning
Pjusken_
26.04.2021 kl 09:34 7125

https://www.youtube.com/watch?v=UgKqfyNF51g

Her blir Bemcentinib nevnte som en av 9 mulige medisiner mot Covid. Fersk rapport.

Of the nine drugs found to reduce SARS-CoV-2 replication in respiratory cells, three already have FDA approval: the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin. These could be rapidly tested in human volunteers and COVID-19 patients. The experiments also shed light on key processes the coronavirus uses to infect different cells and found that the antiviral drug remdesivir, which has an FDA Emergency Use Authorization for treating COVID-19, does appear to work against the virus in cell-culture tests on respiratory cells, whereas hydroxychloroquine does not.

The study highlights cyclosporine as particularly promising, as it appears to works against SARS-CoV-2 in respiratory and non-respiratory cells, and via two distinct mechanisms: inhibiting cell enzymes called cyclophilins, which the coronavirus hijacks to support itself, and suppressing the potentially lethal inflammation of severe COVID-19.


The Nine Drugs Found to Reduce SARS-CoV-2 Replication in Respiratory Cells:
AZD-8055 https://www.vulcanchem.com/product/in...​
Bemcentinib https://www.vulcanchem.com/product/in...​
Cyclosporine https://www.vulcanchem.com/product/ap...​
Dacomitinib https://www.vulcanchem.com/product/in...​
Ebastine https://www.vulcanchem.com/product/in...​
Salinomycin https://www.vulcanchem.com/product/in...​
WYE-125132 https://www.vulcanchem.com/product/in...​
Y-320 https://www.vulcanchem.com/product/in...​
Dp44mT https://www.vulcanchem.com/product/in...

long41 skrev Innlegget er slettet
Thumb up.
Pjusken_
26.04.2021 kl 10:05 6945

Bra initiativ..godt jobbet!
mimer
26.04.2021 kl 10:15 6855

long41 skrev Innlegget er slettet
🤙
maraud
26.04.2021 kl 10:27 6809

long41 skrev Innlegget er slettet
Veldig bra long41 :-)
Link til f. eks Radforsk sin podkast med intervju av R Godfrey er også interessant for nye .. Dette er siste med Bergen Bio: https://soundcloud.com/user-972208711/episode-164


long41 skrev Innlegget er slettet
Supert initiativ!
King
26.04.2021 kl 11:43 6783

Forumet virker lettere å være på nå og innleggene har blitt saklige og interessante. Kan det skyldes at de mest negative har solgt seg ut og har forduftet? Litt synd på de som solgte seg ut på bunnen før helgen men i alle aksjer er det viktig å ha en plan og en viss langsiktighet og ikke kjøpe og selge basert på intuisjon. BGBIO sin pipeline er fortsatt like robust.
BioBull
26.04.2021 kl 12:07 6654

Skikkelig deilig og trangt i heisen oppover i dag.

Fortsatt maaange etasjer til før jeg skal ut... 😎

Bill.mrk. 2500 NOK


Skjul BEMCENTINIB PRE-CLINICAL COVID-19 DATA TO BE PRESENTED AT VIRUTAL IMMUNOLOGY 2021

ANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON

    Newsweb

Bergen, Norway, 26 April 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a poster presentation on pre-clinical COVID-19 data has been accepted for presentation at Virtual Immunology 2021, taking place from 10-15 May 2021. Virtual Immunology 2021 is the 104[th] annual conference of the American Association of Immunologists. The presentation illustrates findings from a pre-clinical study conducted by BerGenBio's scientific collaborator Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa, to evaluate AXL as a therapeutic target for COVID-19 and the potential effect of BerGenBio's selective AXL inhibitor bemcentinib, shown to inhibit SARS-CoV-2 infection in in vitro and in vivo models. The abstract was deemed to be exceptional by the Virtual Immunology 2021 reviewers so the author, Dana Bohan, a PhD candidate from the University of Iowa, will receive a 2021 AAI Late Breaking Poster Award. Poster presentation details at Virtual Immunology 2021 are as follows: Title: Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19 Date: Monday, May 10[th] 2021 Time: 6:30-8:00pm ET The poster presentation will be made available at BerGenBio's website www.bergenbio.com at the date of the presentation. -Ends- About AXL AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters the host cell, and AXL expression is upregulated that leads to suppression of the Type 1 Interferon immune response by host cells and in their environment. Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and promotes the anti-viral Type I interferon response. In cancer, increase in AXL expression has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers. AXL suppresses the body's immune response to tumours and drives treatment failure across many cancers. High AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib, therefore, have potential high value as monotherapy and as the cornerstone of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases including fibrosis. About Bemcentinib Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent and highly selective AXL inhibitor, currently in a broad phase II clinical development programme. It is administered as an oral capsule and taken once per day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine -based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit?www.bergenbio.com Contacts ir@bergenbio.com Richard Godfrey CEO, BerGenBio ASA Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com +47 917 86 513 International Media Relations Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs, Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 Media Relations in Norway Jan Petter Stiff, Crux Advisers stiff@crux.no +47 995 13 891 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

klaesp
26.04.2021 kl 15:05 6136

 pre-clinical COVID-19 data has been accepted for presentation at Virtual Immunology 2021, taking place from 10-15 May .. begynner å litt lei av pre clinical når vi har to ferdige studier...

Pr definisjon er ikke fase 2 studiene ferdig ennå.
BioBull
26.04.2021 kl 15:07 6109

Jeg gleder meg....

Regner med at noen visste om denne pressemeldingen i morges .... 😎

...men jeg tror/håper/regner med at det kommer flere gode nyheter slik kursen beveger seg nå...

Tune In ... Sweet Music Soon !!🎼

🎼Ole B. Bull og fra Bergen !
Ole Bornemann Bull var en norsk fiolinist og komponist i romantikken. Bull var en av den tids største fiolinvirtuoser som trollbandt publikum.

Jeg er bare Bornemann BioBull 😎
Redigert 26.04.2021 kl 15:25 Du må logge inn for å svare
MiniMe
26.04.2021 kl 15:09 6018

«The abstract was deemed to be exceptional by the Virtual Immunology 2021 reviewers so the author, Dana Bohan, a PhD candidate from the University of Iowa, will receive a 2021 AAI Late Breaking Poster Award.»

Gratulerer og Tusen takk BergenBio👏👏
HP17
26.04.2021 kl 15:14 5963

long41 skrev Innlegget er slettet
Dette blir utrolig spennende dager frem til konferansen.
"Title: Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19"

Ikke kom å fortell meg at det ikke er gode funn/data som nå blir presentert her.
klaesp
26.04.2021 kl 15:18 5927

Er selvsagt klar over det👍 Er bare lei av ordet pre_clinical

Har selvsagt et godt håp om at de mennsklige studier er så bra at BP er med som "sponsor " fase 3...fasit i mai👈
Redigert 26.04.2021 kl 15:33 Du må logge inn for å svare
sry
26.04.2021 kl 15:30 5831

Samme skjer igjen. Meldingene er så kryptiske. Først tror mange at det er gode nyheter, så kommer tvilen sigende. Hva er de egentlig sier? Og aksjen faller tilbake igjen.
Pjusken_
26.04.2021 kl 15:37 5790

Grunnet til at kursen går i dette mønsteret er gevinstsikring for de som ikke har nerver og er langsiktig + shorting som konstant presser pris ned. Tror de begynner å få litt panikk..Citadel og co.
peaf
26.04.2021 kl 16:16 5547

Man ler seg nesten ihjel av det her selskapet og dess super naive skribenter, nu har de brukt opp alt av resultater av verdi. Som viste i stort sett null effekt. så nå må de grave frem noen urgamle prekliniske resultater. Og det er jo førståligt når det er bare der de kan finne en påvisbar effekt, nei dette går fint om man lever evigt da kan det hende de tjener penger under livstiden. Men nån garanti er det ikke..
Carrera
26.04.2021 kl 16:46 5357

Nå må du ikke få latteren i halsen!
Naive skribenter???

peaf
23.03.2021 kl 16:10
Og når någet er lovende med kjente resultater, så er det nok bare oppside som gjeller.

peaf
25.03.2021 kl 04:33
Så taler det meste før att her kan det komme meget gode nyheter.

peaf
26.04.2021 kl 16:55 5270

Vet du att det finns noe som heter Wake up, det er noe som du aldri kommer oppleve. Om ikke BEM hjelper på det, da hjelper det på noe i alle fall. men du er vel AXL positiv antar eg.
KOKO19
26.04.2021 kl 16:56 5266

Hvor stort tap realiserte du sist fredag?
King
26.04.2021 kl 17:47 4973

Også jeg som trodde alle utålmodige pessimister var vekk. Skal dette forumet ha noe verdi bør skribentene komme med nyttig informasjon og ikke svada slik som enkelte liret ut av seg i forrige uke. Til og med den kommende virtuelle presentasjonen i mai klarer noen få å oppfatte negativt.